Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia

Neoplasma

Volumn 46, Issue 1, 1999, Pages 61-65

  Al Bahar, S ^a,b   Pandita, R ^a   Bavishi, K ^a   Savani, B ^a  

^a KUWAIT CANCER CONTROL CENTER   (Kuwait)

^b NONE   (Kuwait)

Author keywords

Acute myeloblastic leukemia; Chemotherapy; Cytosine arabinoside; Mitoxantrone

Indexed keywords

CYTARABINE; MITOXANTRONE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NAUSEA; REMISSION; SURVIVAL TIME; VOMITING;

EID: 0032920278     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. ARCHIMBAUD, E., LEBLOND, V, MICHALLET, M., CORDONNIER, C., FENAUX, P., TRAVADE, P., DREYFUS, F., JAUBERT, J., DEVAUX, Y., FIERE, D.: Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood, 77, 1991, 1894-1900.
2. ARLIN, Z.A., SILVER, R., CASSILETH, P., AREMENTROUT, S., GAMS, R., DAGHESTANI, A., COLEMAN, M., SCHOCH, I., DUKART, G.: Phase I-II trial of mitoxantrone in acute leukemia. Cancer Treat. Rep., 69, 1985, 61-64.
3. ARLIN, Z., CASE, D.C., MOORE, J., WIERNIK, P., FELDMAN, E., SALETAN, S., DESAI, P., SIA, L., CARTWRIGHT, K., LEDERLE COOPERATIVE GROUP: Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute non-lymphocytic leukemia (ANLL). Leukemia, 4, 1990, 177-183.
4. BENNETT, J., CATOVSKY, D., DANIEL, M.T., FLANDRIN, G., GALTON, D.A.G., GRALNICK, H.R., SULTAN, C.: Proposals for the classification of the acute leukemias. Br. J. Haematol., 33, 1976, 451-458.
5. BENNETT, J., CATOVSKY, D., DANIEL, M.T., FLANDRIN, G., GALTON, D.A.G., GRALRICK, H.R., SULTAN, C.: Proposed revised criteria for the classification of acute myeloid leukemia. Ann. Int. Med., 103, 1985, 620-625.
6. BERMAN, E., HELLER, G., SANTORSA, J., MCKENZIE, S., GEE, T., KEMPIN, S., GULATI, S., ADREEFF, M., KOLITZ, J., GABRILOVE, J., REICH, L., MAYER, K., KEEFE, D., TRAINOR, K., SCHLUGER, A., PENENBERG, D., RAYMOND, V., O'REILLY, R., JHANWAR, S., YOUNG, C., CLARKSON, B.: Results of a randomized trial comparing idarubicin with cytosine arabinoside with daunorubicin with cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood, 77, 1991, 1666-1674.
7. BISHOP, J.F.: The treatment of adult acute myeloid leukemia. Semin. Oncol., 24, 1997, 57-69.
8. CROSSLEY, R.J.: Clinical safety and tolerance of mitoxantrone. Semin. Oncol., 11, 1984, 54-58.
9. ELLIS, A.L., RANDOLPH, J.K., CONWAY, B.R., GEWITZ, D.A.: Biochemical lesions in DNA associated with antiproliferative effects of mitoxantrone in the hepatoma cell. Biochem. Pharmacol., 39, 1990, 1549-1556.
10. GELLER, R.B., BURKE, P.J., KARP, J.E., HUMPHREY, R.L., BRAIN, H.G., TUCKER, R.W., FOX, M.G., ZAHZURAK, M., MORELL, L., HALL, K.L., PINTADOSI, S.: A two-step timed sequential treatment for acute myelogenous leukemia. Blood, 74, 1989, 1499-1506.
11. HANN, I.M., STEVENS, R.F., GOLDSTONE, A.H., REES, J.K.H., WHEATLEY, K., GRAY, R.G., BURNETT, A.K. on behalf of the adult and childhood leukemia working parties of the Medical Research Council: Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloblastic leukemia: Results of the medical research councils 10th AML Trial (MRC AML 10). Blood, 89, 1997, 2311-2318.
12. KAPUSCINSKI, J., DARZYKIEWICZ, Z., TRAGANOS, F., MELAMED, M.R.: Interactions of a new anti tumor agent 1,4 - dihydroxy - 5,8 - bis [2 (hydroxyethyl) aminoethyl] amino 9, 10-anthracenedione, with nucleic acid. Biochem. Pharmacol., 30, 1981, 231-240.
13. YIN LIU, J.A., JOHNSON, P.R.E., DAVIS, J.M., FLANGAN, N.G., GORST, D.W., LEWIS, M.J.: Mitoxantrone and cytosine arabinoside as first line therapy in elderly patients with acute myeloblastic leukemia. Br. J. Haematol., 79, 1991, 415-420.
14. MAC-CALLUM, P.K., DAVIS, C.L., ROHATINER, A.Z.S., LIM, J., GUPTA, R.K., WHELAN, J.S., PRICE, C.G.A., EVANS, M.L., AMESS, J.A.L., LEAHY, M., JOHNSON, P.W.M., OZA, A.M., LISTER, T.A.: Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence. Leukemia, 7, 1993, 1496-1499.
15. MATHER, F.J., SIMON, R.M., CLARK, G.M., VON HOFF, D.D.: Cardiotoxicity in patients treated with mitoxantrone. Cancer Treat. Rep., 71, 1987, 609-613.
16. MEYER, R.J., DAVUS, R.B., SCHIFFER, C.A., BERG, D.T., POWELL, B.L., SCHULMAN, P., OMURA, G.A., MOORE, J.O., MCINTYRE, O.R., FREI, E. for the Cancer and Leukemia Group B: Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med., 331, 1994, 896-903.
17. PACIUCCI, P., DUTCHER, J., CUTTNER, J., STRAUMANN, J.J., WIERNIK, PH., HOLLAND, J.F.: Mitoxantrone and Ara-C in previously treated patients with acute myelogenous leukemia. Leukemia, 7, 1987, 565-567.
18. PREISLER, H., DAVID, R.B., KRISHNER, J., DUPRE, E., RICHARDS, F., HOAGLAND, H.C., KOPEL, S., LEVY, R.N., CAREY, R., SCHULMAN, P., GOTTLIEB, A.J., MCINTYRE, O.R. and the Cancer and Leukemia group B: Comparison of three remission induction regimens and post induction strategies for the treatment of acute non-lymphocytic leukemia: A cancer and acute leukemia group B study. Blood, 69, 1987, 1441 -1449.
19. RADTKE, H., SCHWARNBORN, J., DAUS, H., HUFUAGEL, D., HERBOTH, R., PREIB, J., PEES, H.W.: Sequential standard dose cytosine arabinoside / mitoxantrone therapy (SAM) in adults with acute myeloblastic leukemia. Haematol. Blood Transf., 34, 1992, 421-424.
20. SHERKENBERG, T.D., VON HOFF, D.D.: Mitoxantrone: A new anti cancer drug with significant clinical activity. Ann. Intern. Med., 105, 1986, 67-79.
21. TEWEY, K.M., ROWE, T.C., YANG, L., HALLIGAN, B.D., LIU, L.F.: Adriamycin induced DNA damage mediated by mammalian DNA topoisomerase II. Science, 226, 1984, 446-468.
22. VAUGHAN, W.P., KARP, J.E., BURKE, P.J.: Long chemotherapy free remission after single cycle timed sequential chemotherapy for acute myeloblastic leukemia. Cancer, 45, 1980, 859-865.
23. VAUGHAN, W.P., KARP, J.E., BURKE, P.J.: Two cycle timed sequential chemotherapy for adult non lymphocytic leukemia. Blood, 64, 1984, 975-980.
24. VOGLER, W.R., VELEZ-GARCIA, E., WEINER, R.S., FLAUM, M.A., BARTOLUCCI, A.A., OMURA, G.A., GERBER, M.C., BANKS, P.L.: A phase 3 trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A southeastern cancer study group study. J. Clin. Oncol., 10, 1992, 1103-1111.
25. WIERNIK, P.H., BANKS, P.L., CASE, D.C. JR, ARLIN, Z.A., PERIMAN, P.O., TODD, M.B., RITCH, P.S., ENICK, R.E., WEITBERG, A.B.: Cytarabin plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood, 79, 1992, 313-319.